Abstract:Background: Methotrexate cutaneous ulceration is a rare methotrexate complication, and has only been described in case reports and case series. Objective: To document patient characteristics, morphologic features, and mortality risk factors for methotrexate cutaneous ulceration. Methods: A systematic literature review of PubMed and Embase (last date 1 November 2021) was performed with data collected from case reports and case series. This study was limited to cases of cutaneous ulceration; presence of oral ulceration was collected from within these cases. Results: 114 cases (men = 57.9%, mean age = 61 years) of methotrexate cutaneous ulceration met inclusion criteria. Psoriasis (69.3%), rheumatoid arthritis (18.4%), and mycosis fungoides (6.1%) were the most common indications for methotrexate use. Morphologies included erosions localized to psoriatic plaques (33.3%), epidermal necrosis/necrolysis (35.1%), localized ulceration (16.7%), and skin-fold erosions (5.3%). Methotrexate dose preceding toxicity varied greatly; median 20 mg/week, interquartile range 15-40 mg/week, range 5-150 mg/week. Most patients had risk factors for serum toxicity (baseline renal dysfunction = 37.8%, concurrent NSAID use = 28.1%, inadequate folic acid use = 89.1%). Thirty percent of cases involved mistakenly high methotrexate doses. Fourteen patients (12%) died. Absence of folic acid use (69% vs. 100%, p value < 0.001), pancytopenia (33% vs. 86%, p value < 0.001), and renal dysfunction at presentation (47% vs. 92%, p value < 0.001) were associated with increased mortality. Limitations: Selection bias present due to abstraction from case reports and case series. Conclusion: Methotrexate cutaneous ulceration is commonly preceded by dosage mistakes, absence of folic acid supplementation, and concurrent use of nephrotoxic medications. Renal impairment, pancytopenia, and absence of folic acid supplementation are key risk factors for mortality from this adverse medication reaction. Providers should regularly monitor methotrexate dosing adherence, drug-drug interactions, and perform routine laboratory evaluation. Index of suspicion for this toxicity should remain high given the varied clinical presentation and high mortality.

Methotrexate Treatment in Children with Febrile Ulceronecrotic Mucha-Habermann Disease: Case Report and Literature Review

Febrile ulceronecrotic Mucha-Habermann disease - a case and treatment review

Two Pediatric Osteosarcoma Cases with Delayed Methotrexate Excretion: Its Clinical Course and Management.

Methotrexate Cutaneous Ulceration: A Systematic Review of Cases

Methotrexate for the treatment of pediatric alopecia areata

Methotrexate-induced Mucositis: Report of Two Cases and Review of the Literature

A case report of febrile ulceronecrotic Mucha-Habermann disease

Methotrexate-induced hypersensitivity syndrome:a case report and literature review

Febrile Ulceronecrotic Mucha-Habermann Disease Associated With Hemophagocytic Lymphohistiocytosis: A Case Report and Review of the Literature

A Case of Febrile Ulcerone-Crotic Mucha-Habermann Disease

Febrile Ulceronecrotic Mucha-Habermann Disease: Treatment with Infliximab and Intravenous Immunoglobulins and Review of the Literature

Multiple Ulcers in the Ileum and Lymphadenopathy Following the Usage of Methotrexate in a Patient With Rheumatoid Arthritis: A Case Report

Severe toxic effects of low-dose methotrexate treatment for placenta accreta in a patient with methylenetetrahydrofolate reductase mutations

Mucha‐Habermann disease: a pediatric case report and proposal of a risk score

Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines

A Rare Case of Acute Methotrexate Toxicity Leading to Bone Marrow Suppression

The Unseen Danger of Methotrexate Toxicity

Epstein-Barr virus-positive mucocutaneous ulcer resulting in severe methotrexate intoxication: a case report

Rapid recovery in a child with febrile ulceronecrotic Mucha‐Habermann disease following intravenous immunoglobulin administration

How can we optimize the use of methotrexate to treat pediatric patients with inflammatory skin diseases?

[Single Methotrexate Chemotherapy for Low-Risk Gestational Trophoblastic Tumor].